The last few years have seen the development of a branch of somatic gene therapy which aims at strengthening the immune surveillance of the body, leading to eradication of disseminated cancer tumor cells and occult micrometastases after surgical removal of the primary tumor. Such a tumor vaccination protocol calls for cultivation of the primary tumor tissue and the insertion of one of three types of genes into the isolated cultured tumor cells followed by irradiation of the transfected or transduced cells to render them incapable of further proliferation. The cells so treated constitute the 'tumor vaccine'. A review of the literature suggests that for mouse models, in the initial period after inoculation, rejection of the tumor cells is usually effected by non-T-cell immunity, whereas the long-term systemic immune response is based on cytotoxic T-cells. High expression of the gene inserted into the tumor cells may be critical for the success of the vaccination procedure. Examples are given which indicate that transferrinfection, a procedure to introduce genes by adenovirus-augmented receptor-mediated endocytosis, meets some important prerequisites for successful application of this type of gene therapy.
INTRODUCTION
The major obstacle to immunotherapy of cancer is the poor immunogenicity of tumors, especially in man. This is somewhat surprising since the large number of genetic alterations found in advanced cancers should give rise to peptide neo-epitopes capable of being recognized in the context of MHC-I molecules by cytotoxic lymphocytes (Lurquin, 1989) . Indeed, tumor-associated (Groen, 1987) and tumor-specific antigens (Van der Bruggen and Van den Eynde, 1992) which should be targets for immunological attack have recently been identified. It is therefore possible that the immune system fails to eliminate tumors not because neoantigens are absent, but rather because the response to these neoantigens is inadequate (Fearon et al., 1990 ). In recent years it has been discovered that transfection of certain genes into tumor cells can render them more immunogenic and, therefore, less tumorigenic. These genes fall into three categories.
( 1 ) Genes expressing proteins which are,foreign to the rrpertoire c$ tutnur cells Such xenogenizatjon of tumor cells can be brought about, for example, by expressing syngeneic MHC-I antigens in MHC-I deficient tumor cells, expressing allogeneic MHC-I or MHC-II antigens or expressing viral proteins such as hemagglutinin (for references see Table I ). Xenogenization can also be brought about by mutagenesis of tumor cells (Van Pel and Boon, 1982) to yield Turn-cell clones which elicited a rejection response in syngeneic mice (reviewed in Van der Bruggen and Van den Eynde, 1992) .
The goal of this operation is to activate the immune system so that it recognizes the tumor cells as foreign and rejects them. The insertion of cytokine-encoding genes such as itlterlcukin. colony stit~uI~~ting factor and interferoll-eI~coding genes, into tumor cells nearly uniformly reduces the tumorigenicity of injected tumor cells with the known exceptions so far of IL-6 which actually leads to an accelerated growth of injected cells, and of TNF-cx or IFN-y, where only partial reduction of tumorigenicity is obtained (see Table II ). In most instances, where tested. a systemic protection against the parental tumor has been observed. However, no such systemic protection was detected after IL-4 (exception see Columbek et al., 1991) , G-CSF or TNF-x transfection of tumor cells (see Table II ).
( 3 f Genes rncoding ricirssary proteins
The properties of xenogenized tumor cells have been explained by the concept of associative recognition (Lake and Mitchison, 1976; 1977; Kenne and Foreman, 1982) which proposes that minor cell surface antigenic differences (as in the case of cancer cells) are insu~cient for the induction of an immune response, The addition of more powerful antigens to the cell surface not only provides for a response to the added antigens but also induces immunorecognition of the original tumor-associated cell-surface antigens (Fearon et al., 1988) and systemic protection against the tumor cell (see Table I ).
The aim of this operation is to impart features of antigen presenting cells to the tumor cells. The CD28 antigen on CD4+ and CD8' T-cells is the primary receptor for the activating antigen B7. CD28 binds to B7 in the absence of other accessory molecules. Interaction between these two antigens is co-stimulatory for T-cell activation (Linsley et al., 1991) . The two-signal model (Janeway, 1989; Nossal, 1989 : Schwartz, 1989 postulates that for optimal activation lymphocytes require both an antigenspecific signal delivered through the T-cell receptor and a second signal, a non-specific co-stimulatory signal such as B7.
The precursor of these xenogenization experiments utilizing gene transfer is the systemic protection elicited against tumor cells by infecting them with virus expressing new antigens on tumor cells or yielding viral oncolysates (Lindenmann and Klein, 1967; Wallack et al., 1977; Ito et al., 1990; Lehner et al., 1990; Liebrich et al., 1991) . This model suggests that immunogenic tumors which do not express I37 can escape destruction by the immune response because tLirnor-targeted T-cells receive inadequate co-stimulation. This leads to the proposition that transfer of a gene encoding the co-stimulatory ligand B7 into melanoma cells, when introduced into a syngeneic mouse, would induce rejection of these cells in vivo. Recently two groups (Chen et al., 1992; Townsend and Rollins and Sunday (1991) "Ctk =cytokine. bab. = absent or strongly reduced, depending on the level of cytokine production;
part. = partial tumorigenicity; act. = accelerated.
'nd. = not done.
Allison , 1993) showed that this concept is indeed valid for melanoma cells. Rejection of B7-transfected tumor cells was primarily mediated by CD8' T-cells and anti-CD4 antibodies ablating CD4 cells had no effect.
Moreover, a systemic protection against the parental B7 tumor cells was obtained (Chen et al., 1992; Townsend and Allison, 1993) . These results open the door for experimentation with other accessory, co-stimulatory molecules which impart certain features of antigen presenting cells to tumor cells. The introduction of syngeneic MHC-II antigen (Table I) 
(b) In some instances initial rejection of the tumor cells is based on non-T-cells
Interestingly, tumorigenicity of tumor cells during the 'vaccination' step (initial injection) is also strongly diminished for IL-4 and G-CSF-secreting tumor cells when tested in nude mice which are deficient for T-cells (Colombo et al., 1991; Golumbek et al., 1991) . This suggests that the initial rejection of tumor cells is supported by a non-T-cell response. By contrast, no reduction of tumorigenicity is seen in nude mice in the case of IL-7
and IFN-y-secreting tumor cells (see Table III ). This is an indication that IL-7 and IFN-y induce a T-cell medi- tumor model chosen, the number of cells itijcctcd and levels of cytokinc secretion. Thus a whole spectrum o1 results has been reported, from no reduction of tumorigenicity in nude mice (Ohe et al.. 1993) to partial and full rejection of IL-2-producing tumor cells, depending on the level of IL-2 secretion (Russell et al., 1991 : Porgador et ~11.. 1993 . These findings have been interpreted as meaning that for low secretors, reduction in tumor growth in immune competent mice is mostly due to T-ceil activity, whereas for high IL-2 secretors a non-T-cell dependent mechanism is at work (Porgador et al., 1993) . et al., 1991) . Similarly IL-4-producing plasmacytoma cells evoke infiltrated eosinophiles and macrophages (Tepper, 1992) . NK cells are not likely to be involved. since NK-depicted mice are nevertheless protected from tumor development (Columbo et al., 1991) . In the same vein, IFN--fproducing tumor cells show infiltration of Thy I ' small lymphocytes (Watanabe et al.. 1989 ) whereas IL-7-producing, and in some cases IL-2-producing, cells (Pardoll, 1992) are marked by infiltration of T-cells as well as macrophages (Hock et al.. 1991 ) . This again corrclates with the data in Table III where the nude mouse system fails to reject IFN-;I-and IL-7-producing tumor cells. As already mentioned the behavior of IL-2 producers is not uniform. In some systems the inocula arc infiltrated by T-cells (Pardoll, 1992) while in others the presence of macrophages and mast cells has been noted (Fearon et al., 1990) .
A recent study is particulary informative (Hock et al., 1993) because the behavior of a single tumor cell line (5558) secreting a series of difierent cytokines has been investigated.
At early times after injection of the inocula. IL-2-, IL-4-, TNF-lx-and IFN-n/-producing 5558 cells showed suppressed tumorigenicity in the immunodeficient nude, SCID, beige and NIHIII mice, but tumors eventually arose with a delay of 3 weeks in comparison with mice injected with the parental cell line. IL-7-producing tumor cells were not rejected. This is confirmatory evidence that most cytokines can elicit a T-cellindependent mechanism capable of suppressing tumor growth in a first, early phase after injection. The late outgrowth of tumors noted above was shown to be correlated with a partial or complete loss of cytokine production in cytokine-producing cells presumably through a selection process for a non-cytokine-producing population of cells.
A correlation of the behavior of the tumors with the immunohistology of the injection site after 3-13 days in immunocompetent mice has been made (Hock et al., 1993) : IL-2-, IL-7-and TNF-a-producing inocula were already infiltrated by T-cells at early time points. T-cells were also observed in IL-4-producing tumors but not until 1 week after injection. In the case of IL-2 producers, CD8+ but not CD4+ infiltrates could be found. IL-7-and IFN-y-secreting tumors were densely infiltrated with both CD4+ and CD8+ cells. However, the predominant cell type found in the infiltrates of all cytokine producers excepting IL-7 producers were macrophages, which presumably accounts for the rejection of these tumors in the nude mouse at early times.
(c) Systemic long-term tumor rejection is based on CTLs
Mice which have been immunized with transfected tumor cells producing a variety of cytokines such as IL-2, IL-4, GM-CSF, or IFN-)I, develop a systemic immune response which protects the animals from tumor growth after challenge with non-transfected tumor cells at a site distant from the primary immunization site (see also  Table II ). This protective activity is maintained for a prolonged period of time. For instance, Gansbacher et al. (1990a,b) observed complete protection in a CMS-5 fibrosarcoma model, even when the challenge was performed 6 weeks after the immunization with IFN-ysecreting tumor cells. Ley et al. (1991) demonstrated partial prevention of tumor growth when the challenge was made 90 days after immunization with IL-2-producing mastocytoma cells. Fearon et al. (1990) , however, found a less persistent protection in a colon carcinoma model where the immune response induced by IL-2-transfected CT26 cells lost 50% of its efficacy within 4 weeks.
There are several lines of evidence that this prolonged systemic immune response is mediated by CTLs. Many groups (e.g., Fearon et al., 1990; Gansbacher et al., 1990a,b; Golumbek et al., 1991; Ley et al., 1991; Dranoff et al., 1993) have demonstrated an increase of CTL activity upon immunization with cytokine expressing tumor cells. The actual contribution of CTLs to tumor rejection has been confirmed in that depletion of CD8+ cells in immunized mice abolishes the ability to suppress tumor growth. In the case of GM-CSF-producing B16 melanoma cells, CD4+ T-cells are required in addition to CD8+ cells for systemic protection (Dranoff et al., 1993) . The observation that the systemic immune response is specific to the tumor used for immunization, and that the growth of non-cross-reactive syngeneic tumors is not affected, underlines the role of CTLs for the generation of a tumor-specific, MHC-I-restricted, systemic immune response against the parental tumor in these models (Fearon et al., 1990; Gansbacher et al., 1990a,b) . Since the tumor tissue may be heterogeneous due to tumor progression it may be desirable not to select for transfected or transduced cell clones, as has been done in most experiments reported up to now (see Table II ). This procedure, besides being time consuming and delaying unnecessarily the application of the 'tumor vaccine', may inadvertently lead to selection of an unrepresentative cell clone. Furthermore, extensive culturing and expansion of cells may lead to a loss of the tumor antigen. A procedure by which the bulk of the tumor cells can be transfected soon after removal and culture would seem desirable.
We believe that our recently developed transferrinfection procedure (Cotten et al., 1992; Curie1 et al., 1992; Wagner et al., 1992; Zatloukal, 1992) has many advantages over retroviral transduction or DNA transfection followed by clonal expansion of the genetically modified cells (see Table II ).
Transferrinfection is a new transfection protocol in which the plasmid DNA to be transported into the tumor cell is reacted with transferrin-polylysine to form highly condensed round particles with a diameter of approx. 100 nm, referred to as 'donuts' (Zatloukal et al., 1992) . These 'donuts' are linked to Ad5d1312 or AdSd11014, which, owing to its endosomolytic property, greatly enhances the receptor-mediated transfer of genes into cells and ultimately into the cell nucleus (Cotten et al., 1992; Curie1 et al., 1992; Wagner et al., 1992; Zatloukal et al., 1992) . We show below that transferrinfection of tumor cells with IL-2-producing plasmids leads to secretion of cytokines at high levels (cf. "To generate the transfer complexes. 2 x 10" biotinylated Ad5d1312 in 100 ml HBS (20 mM Hepesjl50 mM NaCl) was mixed with streptavidinylated poiylysine (0.5 ug) in 100 ml HBS and incubated for 30 min at room temperature. Thereafter, 6 ug of plasmid DNA (IL-2 or IFN-y) in 150 ml HBS were added, mixed thoroughly and incubated for 30
min. Finally, polylysine-modified human transferrin (7.5 ug) in 150 ~1
HBS were added, mixed thoroughly and incubated for a further 30 min.
For transf~ction the complexes were applied to M3 cells (3 x 10') in a total volume of 2 ml culture medium. After 4 h of incubation at 37 C the complex-containing medium was removed and fresh medium con- As can be seen in Table IV the control mice all developed tumors within 2 weeks after inoculation.
All mice challenged with IL-2-producing M3 cells remained free High levels of IL-2 secretion of between 2 x 10" and 10" units/lo" cells per 24 h can be obtained in vitro by transferrinfection of murine M3 melanoma cells. The desired levels of IL-2 production can be adjusted simply by mixing the IL-2 expression vector with plasmid devoid of the It-2 cDNA.
That the high level of IL-2 secretion is an important "Transfer complexes were generated as shown in Table IV for IL-2 100% and IFN-T 10%. IFN-y plasmids were diluted out with parental plasmid pSP in a ratio of 10: 90. IL expression was: IL-2 100% = 3 x lo4 u/lo6 cells per 24 h; IFN-y 10% =800 ng/106 cells per 24 h.
feature for eliciting systemic protection can be seen from Table VI . M3 melanoma cells were transferrinfected with the IL-2 gene to reach secretion levels of 3 x lo4 units/lo6 cells per 24 h in vitro. In order to reduce the level of IL-2 production, the IL-2 plasmid was mixed with the parental plasmid pSP which did not contain the CMV IL-2 gene construct (in a ratio of 4 : 96). The secretion rate obtained was 400 units IL-2 per 106/24 h. For vaccination, groups of mice, usually six, were injected with irradiated (2000 rad) IL-2-producing M3 cells at the two different levels indicated above. Injection was into the left flank on day 0 and day 7, as above, followed by a challenge with lo', 3 x lo5 and lo6 live tumorigenic M3 cells injected into the right flank on day 14. As shown in Table VI , all nonimmunized mice developed tumors within 3 weeks. Three out of six mice vaccinated with irradiated cells which had been transfected with the parental plasmid devoid of the IL-2 gene developed tumors, suggesting that transfected and irradiated M3 tumor cells were partially immunogenic. Mice vaccinated with irradiated high-level IL-2 producers afforded complete and lasting protection even Challenge with 10' KLN205 cells IL-2 (3 x lo4 u) 616 _ "The transfer complexes were generated as shown in Table IV except that Ad5d11014, 8-methoxypsoralen (8-MOP)/UV-irradiated, was used.
For high-producer M3 cells 6 ug IL-2 plasmid DNA was used. For the low IL-2 producers the 6 ug DNA consisted of IL-2 plasmid diluted out with the parental plasmid without insert (pSP) in a ratio of 4:Y6. Tumor load was scored 3 weeks after tumor challenge.
with challenges as high as 3 x lo5 cells, but at lo6 cells l/4 mice developed a small tumor. By contrast, low IL-2-producing cells did not withstand a challenge with 3 x lo5 cells, 3/5 mice developing tumors. The high IL-2 producers did not protect against a challenge with a low dose of KLN205 cells showing that the protection in the above experiments was tumor-specific.
(h) Conclusions
The examples given in Tables IV-VI clearly demonstrate that transferrinfected M3 cells express cytokines at high levels and over a period long enough to suppress tumorigenicity of their cells and in the case of high IL-2 secretors impart systemic and lasting protection against a challenge of highly tumorigenic cells. Our results reinforce the concerns of Dranoff et al. (1993) and suggest that high levels of cytokine production may be necessary for high efficacy of 'tumor vaccines'.
